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Background: Staphylococcus aureus (S. aureus) is one of the earliest bacteria detected in infants and children with cystic fibrosis (CF). The rise of
methicillin resistant S. aureus (MRSA) in the last 10 years has caused a lot of attention to this organism.
Results: The aim of this review is to provide a general overview of methicillin sensitive S. aureus (MSSA) and MRSA, discuss special aspects of S.
aureus in cystic fibrosis, and to review treatment concepts.Microbiology of the organismwill be reviewed alongwith data regarding the epidemiology of
bothMSSA andMRSA.Antibiotic treatments both in regards to acute management and eradication ofMSSA andMRSAwill be reviewed. Prophylaxis
of MSSA in CF remains controversial. Treatment with anti-staphylococcal agents reduces the infection rate withMSSA but may lead to a higher rate of
infection with P. aeruginosa. In regards to MRSA, there is a paucity of clinical data regarding approaches to eradication.
Conclusions: To advance the care of CF patients, controlled clinical trials are urgently needed to find the optimal approach to treating CF patients
who are infected with either MSSA or MRSA.
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Table 1
Prevalence of MSSA and MRSA in different countries in 2007 and 2008.




2007 2008 2007 2008
USA [27,33] 50.9 51.3 22.6 23.7
France [34] 50.6 52.1 9.9 8.5
Ireland [35] 54.0 51.0 13.0 11.0
Australia [36] 44.2 44.7 2.5 3.0
Canada [37] 45.8 3.2
Belgium[38] 56.3 56.3 7.3 8.2
United Kingdom a [39] 17.3 15.2 3.5 2.7
a In the UK, MSSA that is captured is defined as chronic. All other nations
capture any positive respiratory culture.
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Staphylococcus aureus (S. aureus) is one of the earliest
bacteria detected in infants and children with CF. This may in
part be due to abnormal host defense to infection recently noted
in the airway of a newborn CF pig model [1]. It is the most
prevalent organism among US CF children with a peak
prevalence between ages 11–15 years [2]. The rise of
methicillin resistant S. aureus (MRSA) in the last 10 years
has caused a lot of attention to this organism. Rates of
methicillin sensitive S. aureus (MSSA) and MRSA are
considerably lower in most European CF centers (see
Table 1). Infection of the CF upper and lower airways are
commonly polymicrobial, can grow in biofilms and once
established rarely can be eradicated with antimicrobial therapy
[3]. For instance, chronic P. aeruginosa, especially in the
mucoid phenotype growth, can rarely be eradicated; however
newly acquired P. aeruginosa can be eradicated successfully
from the lower airway; this in turn may have profound
implications for disease progression in CF. It is unclear whether
such an eradication approach will have similar efficacy and
safety when targeting other pathogens such as MSSA and
MRSA. The aim of this review is to provide information
relevant to CF on MSSA and MRSA, and to review treatment
concepts for MSSA and MRSA.
2. Microbiology of S. aureus and MRSA
S. aureus, a gram positive coccus, is a ubiquitous bacterium
and is a commensal of the human skin, especially anterior nares
and skin creases in CF and non-CF. An estimated 30–50% of
healthy subjects are intermittently or chronically colonized with
S. aureus, with chronic nasal carriage being a risk factor for S.
aureus bacteraemia [4]. S. aureus grows typically aerobically
but also as facultative anaerobe and is capable of biofilm
formation. For epidemiological purposes multiple typing
systems have been developed for MSSA and MRSA. These
include pulse-filed gel electrophoresis (PFGE), multilocus
sequence typing (MLST), and typing of the variable tandem
repeat region of staphylococcal protein A (spa typing).
Additionally MRSA isolates are distinguished by the Staphy-
lococcal Casette Chromosome (SCC)mec types, which carries
the gene for methicillin resistance. To date, at least eight
SCCmec types have been distinguished, however new types are
being described [5]. Whereas SCCmec types I, IV, and V
encode exclusively for beta-lactam resistance, the larger
SCCmec types II and III carry non-beta-lactam antibiotic
resistance genes.
Since 1960 ~80% of all S. aureus isolates have been
resistant to penicillin and within 2 years of introduction of
methicillin in 1959, S. aureus strains developed resistance to
methicillin through the acquisition of the mecA gene (MRSA).
Early MRSA isolates were only associated with hospital
acquisition (HA), however since approximately 1990s, com-
munity associated (CA)MRSA emerged. CA-MRSA generally
differs in genetic background from HA-MRSA, is associated
with SCCmec IV, V or VII, and tends to be resistant to fewerantibiotic classes. Given outbreaks of CA-MRSA in the
hospital or HA-MRSA spreading into the community [6], the
distinction between HA- versus CA-MRSA is increasingly
difficult. Genetic interchange between MRSA strains also
make molecular classification complicated [7]. Classification
as CA- versus HA-MRSA in fact may vary depending which
approach is employed: epidemiologic, SCCmec type, PVL
status, or sensitivity to clindamycin [8]. Worldwide, CA-
MRSA strains differ in their SCCmec type, PFGE pattern, and
MLST and spa profiles; in the US for instance the most frequent
strain is USA-300, which is increasingly being reported in
European countries in CF or non CF subjects [9].
S. aureus isolates harbor a multitude of virulence factors,
which overlap to a large degree in MSSA and MRSA. The
leukocytolytic toxin Panton-Valentine leukocidin (PVL) is
more frequently expressed in MRSA than MSSA strains. PVL
has been epidemiologically associated with severe cutaneous
infections and has initially been attributed as the main cause for
severe, necrotizing lung infections based on clinical observa-
tions and experiments in animals using isolated PVL [10]. More
recently the role of PLV as the main virulence factor for
necrotizing lung infections has been questioned [11]. Expres-
sion of PVL is also associated with altered regulation (both
increases and decreases) of cell wall anchored secreted proteins.
Toxin expression is regulated by many factors for instance
anaerobic growth and subinhibitory concentrations of antibi-
otics as seen in CF infections [12–14].
Special aspects of S. aureus associated with chronic infection
as seen in CF lung disease are the appearance of small colony
variants (SCV). Distinction of SCV are based on colony size on
the agar plate, slower growth, non-pigmentation, reduced
production of alpha-toxin, and thymidine dependence. There is
evidence that exoproducts of P. aeruginosa enhance SCV
formation and conversely SCV growth provides a survival
advantage for S. aureus in presence of P. aeruginosa infection
[15]. Clinically, SCV are associated with higher rates of anti-
microbial resistance and more advanced lung disease in CF [16].
Chronic S. aureus infection in CF lung may occur as biofilms
which is associated with higher in vitro antibiotic resistance.
Biofilm mode of growth occurs in MSSA and MRSA regardless
of genetic background [17] and mixed, likely multi-bacterial
biofilms exist in chronic CF lung infection. Importantly in regards
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rates (i.e. hypermutators strains) during CF lung infection
compared to nasal colonization in healthy subjects [18].
S. aureus isolates, like P. aeruginosa, have clearly been
shown to persist in CF patients over years. In a large survey of S.
aureus in six French hospitals, 85 of 238 patients who were
culture positive for S. aureus, had three or more consecutive
isolates over at least 6 months [19]; this same group showed that
48% of the subjects harbored the identical isolate by pulse field
gel electrophoresis up to 28 months [20]. Data from two large
randomized controlled trials corroborated this data. One study
noted persistence of S. aureus for a median of 37 months with
most of the subjects harboring a single clone [21]. Interestingly,
SCV S. aureus persisted no longer than normal S. aureus.
2.1. Molecular characteristics and antimicrobial susceptibilities
in CF MRSA isolates
Some studies in the US examined MRSA isolates obtained
from patients at their centers and showed that about 30% were
SCCmec IV [22–24]. More recently acquired MRSA was more
likely to be SCCmec IV [22]. This pattern is similar to reports
from European centers, for instance a multi-center study in Italy
showing 38% being CA-MRSA defined as SCCmec IV [25].
An ongoing six-center observational study in the US (STAR-
CF, Muhlebach, PI) examines the clinical impact of different
MRSA strains characterized by molecular typing [26]. Of the
over 200 isolates that have been obtained from pediatric patients
with chronic MRSA infection, 69.5% are pvl negative SCCmec
II, consistent with HA-MRSA. The remaining isolates are
SCCmec IV and 13% are pvl negative and 17% are pvl positive.
Antimicrobial susceptibilities show that over 90% of isolates are
resistant to erythromycin and show high resistance rates to
quinolones (90% for HA and 35%% for CA isolates). On the
other hand resistance to TMP-SMX and tetracycline was below
10% for CA or HA isolates indicating that these are good first
choices for first isolation of MRSA as the overall rate of
resistance is low and they both have an advantageous risk/
benefit profile. In this sample of pediatric isolates resistance to
linezolid was 1% and no isolate was resistant to vancomycin,
thus these medications should be reserved for treatment of
severe exacerbations.
3. MSSA and MRSA clinical epidemiology and impact
3.1. MSSA
Early infections in CF airways are most frequently caused by
S. aureus and H. influenzae [27]. In fact, S. aureus is often the
first organism cultured from young children with CF and is
detected in bronchoalveolar lavage cultures or oropharyngeal
swabs in young children with CF [28]. The overall frequency of
MSSA and MRSA by country as reported by their National CF
Registries is shown in Table 1. Patients with CF participating in
a large phase 3 clinical trial in the US who had P. aeruginosa at
entry, also were culture positive for S. aureus in 43.2% (201
patients) [29]. S. aureus in combination with P. aeruginosamayportend worse clinical outcomes as noted in a study of CF
children under age 2; those who were positive for S. aureus and
P. aeruginosa on throat cultures had lower Brasfield scores and
by age 5 had worse obstructive lung disease than those with S.
aureus alone [30]. Pulmonary infection with S. aureus and
inflammation in bronchoalveolar lavage also correlated with
worse nutritional status in the prospective Australian trial
including mostly infants diagnosed with CF by newborn
screening [31]. Early studies of immune response to S. aureus
in CF patients noted increases in serum IgG antibodies to
teichoic acid and alpha toxin but not capsular antibodies from S.
aureus in those subjects chronically infected and found a
reduction in the antibody panel with treatment of S. aureus [32].
There continues to be debate about the significance of S.
aureus in the pathogenesis of lung infection in the general CF
population [33] despite increased inflammatory response with
S. aureus infection. This controversy has stemmed from
findings that treatment (often prophylactic) of S. aureus may
lead to earlier acquisition of P. aeruginosa as discussed below.
3.2. MRSA
Infection with MRSA, which was formerly seen only in
hospitals has increased in frequency both as nosocomial
infection (recent US reports suggest that 40–80% of nosoco-
mial infections are MRSA) but also as infections in previously
healthy subjects [34]. National prevalence in the US among CF
patients rose from 2% in 2001 to 22.6% in 2008 [27].
Comparisons with other nations are noted in Table 1. Recent
epidemiologic studies employing large multi-center longitudi-
nal databases have evaluated the role of MRSA as contributor
to clinical outcomes in CF [35,36]. In a cross-sectional study,
Ren and colleagues have shown that CF patients infected with
MRSA as the primary pathogen determined using standard
sputum culturing techniques have lower lung function than
those with MSSA as the only pathogen. Additionally MRSA
positive patients had an increased rate of hospitalization and
oral, inhaled and intravenous antibiotics [35]. Higher treatment
intensity was also seen in a single center study where MRSA
and MSSA patients were matched on P. aeruginosa status, age
and gender. Patients did not differ in nutritional status or lung
function however those with MRSA were prescribed signifi-
cantly more maintenance medications [37]. An additional study
using data from the Epidemiologic Study of Cystic Fibrosis
(ESCF) showed that patients with MRSA had faster decline in
lung function prior to MRSA acquisition noting that MRSA did
not impact lung function decline [36].
Dasenbrook and colleagues evaluated the longitudinal
impact of MRSA acquisition on lung function in patients with
CF [38]. They found that the rate of lung function decline was
greater in those patients with MRSA compared to non-MRSA
patients in patients age 8 to 21 years (FEV1 decline of 2.06%
predicted/year in MRSA compared to 1.44% predicted/year in
those without MRSA, difference— 0.62% predicted/year, 95%
CI −0.70 to −0.54; pb0.001). In addition, known MRSA
infection has been shown to be a risk factor for failure to recover
lung function after an acute pulmonary exacerbation [39]. In an
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CF Foundation Patient Registry, persistent MRSA infection was
found to be associated with increased mortality in CF [40].
Although multiple sensitivity analyses confirmed the robustness
of the primary findings, other markers of disease severity not
fully addressed in the registry data (residual confounders) could
still account for the results. The study may also suffer from an
indication bias, notably sicker patients get treated with broad
spectrum antibiotics and get hospitalized more frequently
leading to higher rates of MRSA infection. All of these studies
raise issues around the management of CF patients with MRSA
positive cultures.
The clinical implications of CA-MRSA versus HA-MRSA
in CF are not clear with very little data in the literature. A recent
report noted adolescent CF patients with PLV+CA-MRSA
presented with febrile respiratory illness and lung abscesses
[41]. This triggered a further review of MRSA at the institution;
of 226 CF children with CF followed at St. Louis Children's
Hospital from 2001 to 2004, 40 were MRSA positive [41]. Six
of these patients grew PLV+CA-MRSA. The patients with
PVL+MRSA were more likely to be admitted for IV antibiotic
therapy and have focal pulmonary infiltrates on chest
radiographs. They also had a greater decline in FEV1 at the
time of MRSA detection compared to their best FEV1 in the
prior year suggesting that PLV+CA-MRSA is more virulent in
CF. These findings have not yet been replicated but are
concerning.
MRSA has other important implications for patients with CF.
In the healthcare environment strict isolation measures have to
be followed for patients infected with MRSA. These measures
lead to patient isolation with negative psychological impact [42]
and have been shown to be associated with worse quality of care
in the inpatient setting [43] and higher costs. Lastly, chronic
MRSA infection in patients with CF may be transmitted to other
CF and non-CF patients. The potential for spread to and from
CF patients in- or outside the healthcare setting makes this a
public health concern. Increasingly spread from the hospital to
the community and vice versa has been described [44,45]. In
fact certain observations and models predict that community
associated infections entering the hospital may become the
predominant source of MRSA in hospitals, thus advocating
eradication in such at risk patients [46].
4. Treatment of MSSA — prophylaxis and eradication
in CF
Some of the first reports of CF lung disease were associated
with S. aureus infection.Historically, significant improvements in
patient longevity have been associated with the advent of anti-
staphylococcal therapy [47,48]. No studies have specifically
evaluated the treatment of acute pulmonary exacerbation in CF
patients infected with MSSA. The studies to date have involved
prophylaxis and eradication. An early placebo controlled clinical
trial that assessed the response to cephalexin as a prophylactic
treatment to prevent S. aureus in 17 subjects with CF [49]
demonstrated clinical benefit in those with S. aureus. Another
group looked at the clinical impact of chronic prophylacticflucloxacillin in CF children; those whowere not on flucloxacillin
had more frequent cough and greater numbers of S. aureus
isolates from their sputum [50].
Despite this early evidence to support early chronic
suppressive treatment of S. aureus, such an approach has
been controversial given the evolving evidence suggesting an
increase in infection with P. aeruginosa with treatment of
MSSA. This association was reported in the early 1980s noting
success in reduction of S. aureus with an increase in P.
aeruginosa [51]. Ratjen and colleagues clearly demonstrated
that one of the sequelae of continuous anti-staphylococcal
treatment is an increased rate of P. aeruginosa acquisition noted
in a retrospective analysis of the German CF registry [52]. The
more definitive data came from a multi-center randomized
placebo controlled clinical trial of cephalexin for healthy CF
children under age 6; in this study antibiotic treatment for 5–
7 years was associated with lower S. aureus rates but higher P.
aeruginosa infection rates [53]. A systematic Cochrane review
noted that anti-staphylococcal treatment if started early in
infancy could reduce S. aureus but noted the increased
prevalence of P. aeruginosa as a concern and in need of
further research [54]. In the US CF Pulmonary Guidelines, the
use of prophylactic anti-staphylococcal antibiotics was not
recommended [55]. The guideline found that any potential
benefit from lower S. aureus infection was “outweighed by
the risk of earlier or more frequent P. aeruginosa infection”
[55]. In the UK guidelines and many Australian territories
however flucloxacillin prophylaxis is recommended starting in
infancy.
Eradication of initial S. aureus infection in CF represents a
different approach than outlined above (chronic suppressive
treatment). One of the earliest reports of attempts to eradicate S.
aureus (MSSA) from the CF airways was a retrospective cohort
study of a Danish CF center following 191 cystic fibrosis patients
treated with 2349 courses of anti-staphylococcal chemotherapy
from 1965 to 79 [56]. They reported eradication of S. aureus in
74%of these subjects after a single course of therapy.With further
treatment, only 9% of subjects were chronically infected with S.
aureus over a 6 month period. In a follow-up study from this same
group they found low levels of resistance developing in 217
patients who had received 1605 courses of anti-staphylococcal
antibiotics (strains resistant to methicillin less than 0.1%, strains
resistant to fusidic acid 1.2%) [57]. Based on these data, the
European CF Consensus group evaluating early intervention in
CF lung disease has recommended an initial 2–4 weeks of anti-
staphylococcal treatment with new S. aureus infection [58]. If this
eradication approach fails, they recommend a 1–3 month course
of antibiotics. The long-term sequela of this treatment approach is
not known and warrants further investigation employing existing
data.
5. Eradication strategies of MRSA
To date there are no conclusive studies demonstrating that
early aggressive treatment of early MRSA respiratory infection
can prevent chronic infection or if this approach ultimately
improves outcomes. Most of the studies are non-controlled case
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between CF and non-CF efforts regarding eradication of
MRSA. Colonization sites in CF patients differ from people
with MRSA in the general population [59] and in chronic care
facilities or the intensive care unit. Importantly, most of the
studies of eradication involved healthcare workers or in patient
populations in chronic care facilities and the intensive care unit
[60]. In these studies, eradication of carrier status has often been
successful using intranasal mupirocin and isolation precautions
only [61]. A meta-analysis and review by the CDC in 2006
included 24 non-experimental studies and these used various
treatment approaches [62]. Guidelines for management of
MRSA provided in non-CF patients differ between the CDC
and Canadian guidelines [63,64] and attempts to eradicate
MRSA colonization in non-CF hospitalized patients have had
variable success.
In CF, the concern about MRSA and the success with early
P. aeruginosa eradication has encouraged several centers to
attempt eradication of MRSA. Eradication protocols have been
tested in a small number of CF patients. A step-wise eradication
protocol has been developed in CF centers in Belfast [65]. In a
non-controlled study of 17 pediatric subjects, MRSA was
successfully eradicated in 94% of the subjects using a 3 step-
protocol. Eight (47%) were successfully decolonized following
one five-day course of oral rifampicin and fusidic acid; this was
repeated for those who did not clear MRSA. A final course of
intravenous teicoplanin was used in four subjects who had still
not cleared the organism. Another protocol advocated at the
Royal Liverpool Children's Hospital focused on the use of
aggressive screening, oral and nebulized vancomycin and
attention to hygiene [66]. In 12 children treated with their
protocol, 7 had MRSA negative cultures on follow-up. The
longest protocol employed in CF employed a 6 month protocol
of oral rifampin and oral fusidate in adults with CF living in
Australia [67]. These subjects had chronic MRSA carriage
(average of 31 months of MRSA isolation). Five of the 7
subjects that followed the protocol had MRSA eradicated
6 months after completing the regimen. In the US, one CF
center recently reported use of a non-formalized protocol to
treat first appearance of MRSA with TMP-SMX for 4 weeks
and mupirocin and rifampin in the last week [68]. Over the
18 months this protocol was used MRSA was successfully
eradicated in 10/17 children. These data are from uncontrolled
studies and most have not evaluated rates of adverse events,
however the results are encouraging in that eradication of
MRSA from CF respiratory secretions is possible using
systemic antibiotics with or without additional topical
therapies. None of the studies evaluated if addition of a
cumbersome topical decontamination is superior to oral
therapy alone. A Cochran collaboration systematic review of
the evidence for the treatment ofMRSA colonization in non-CF
subjects evaluated 6 clinical trials and concluded that there was
insufficient data for efficacy with a high rate of adverse events
associated with treatment (20%) [69]. Given these conflicting
data and limited supportive evidence, our group along with
support from the US CF Foundation has begun a clinical trial
evaluating the safety and efficacy of an eradication protocol forearly MRSA acquisition (≤6 months). The regimen that is
being studied in the US CFF clinical trial in subjects with CF
ages 4–45 years involves using a two week course of oral
rifampin (weight b40 kg: 15 mg/kg daily; weight ≥40 kg:
300 mg twice daily), TMP-SMX (weight b40 kg: 8 mg/kg
trimethoprim/40 mg/kg sulfamethoxazole; weight ≥40 kg:
320 mg/1600 mg twice daily), nasal mupirocin, topical chlor-
hexidine body wash, and environmental cleaning.
6. Treatment options for MRSA
There are no current recommendations or guidelines specific
for MRSA in CF. There is no data regarding the treatment of CF
patients infected with MRSA with an acute pulmonary
exacerbation. A prophylactic MRSA protocol would be very
concerning and likely enhance emergence of further resistance.
A list of the currently approved antibiotics is summarized in
Table 2 (those that are not licensed in US are shaded). The
reader is referred to local prescriber manuals for availability,
dosing information and side effect profiles.
Based on antimicrobial susceptibilities in the current US
observational MRSA study and those reported in other countries
the following antibiotic strategies may be advantageous. In
patients inwhomoutpatient therapy is indicated the initial choices
may include minocycline if patient is older than 8 years or TMP-
SMX at all ages. Fusidic acid has been shown to be an effective
regimen for eradication in combination with rifampin in CF
patients with either initial or chronic colonization [65,67]. For
patients failing these options but where oral therapy is preferred
linezolid is a next option. In children however pharmacokinetics
differs from adults, requiring TID dosing and linezolid levels have
been described to be erratic in CF patients, especially children
[70]. Other reasons to keep linezolid as an option of last choice are
the side effect profile with potential interactions with tri-cyclic
antidepressants, and irreversible neuropathy with long term use.
Resistance to linezolid is increasingly being reported in CF or in
situations with prolonged and frequent use [70,71]. The final
decision on choice of antibiotic needs to include review of
concomitant medications, side effect profile and patient tolerance.
Despite the attractive option of treatingMRSA and P. aeruginosa
with a fluoroquinolone, this class should be used judiciously to
avoid further resistance. Fluoroquinolone resistance occurs faster
with older fluoroquinolones [72], is associated with cross-
resistance to other antibiotics e.g. cephalosporines and aminogly-
cosides and act as selectors for methicillin resistance in S. aureus
[73]. Reduced use of quinolones decreased the rate of MRSA
[74]. Combination of rifampin with other medications has been
shown to decrease emergence of resistance and increase
intracellular penetration and enhance antimicrobial activity of
either agent [82].
Among IV antibiotics, glycopeptides may be the most widely
used choice. Resistance to vancomycin has so far not been a
problem for CF; however heteroresistant vancomycin intermediate
isolates (hVISA) may occur. Hetero-resistant MRSA, or hVISA in
case of vancomycin, is characterized by the presence of
subpopulations with poor susceptibility within a larger population
of fully antimicrobial-susceptible microorganisms. Such hVISA is
Table 2
Current antibiotics used to treat MRSA.
Antibiotic class or name Name/example Tissue and lung penetration Bacterio-static or -cidal Place in therapy CF specific comments
Fusidic acid Moderate sputum levels, no data
in bronchoalveolar lavage
Concentration dependent Early and chronic infection Resistance very low in N America,
higher in other countries a
Sulfon-amide Combined TMP-SMX Concentration in respiratory
secretions parallels those in serum
2–4.5 μg [76]
bactericidal In early and later stages b Good antimicrobial susceptibilities
in different MRSA strains
Tetra-cyclines Doxycycline
Minocycline
Doxy.: Approx. 16% of blood
concentration. Mino.: 50–70% of
serum concentration
-static Nage 8 years only
Early and chronic infection
Good antimicrobial susceptibilities
in different MRSA strains
Oxa-zolidinone Linezolid Good lung penetration -static Reserve for severe/resistant infection Cross-resistance to other antibiotics
unlikely
Lincosamide Clindamycin Good oral absorption and tissue
penetration
-static Only if MRSA is susceptible High rate of constitutive or inducible
resistance in CF [77]





to other antibiotics and induction
of MRSA [78]
Increasing resistance of MRSA
to various fluoroquinolones
Glyco-peptides Vancomycin Poor penetration into lung tissue Slowly bactericidal Exacerbations requiring IV therapy Use additional β-lactam if
co-infection MRSA/MSSA
Teicoplanin Poor lung penetration but better
than vancomycin
bactericidal Cross-resistance with vancomycin
Rifamycin Rifampin Good penetration into respiratory
secretions and for nasal carriage
bactericidal in synergy Only as combination therapy. Resistance varies with drug
concentration. Active against





bactericidal Not tested in CF. Used
for synergy in blood
borne infections
Clinical observations with high dose
inhaled tobramycin indicate no
effect on MRSA
Glycyl-cycline Tigecycline Good tissue/lung penetration -static Only in selected cases, however in
US unlabelled for MRSA
pneumonia
Activity against mycobacteria
and anaerobes. Some in vitro
activity for biofilm MRSA [80]
Footnotes:
a Fusidic acid resistance include genetic mutations in bacteria leading to alterations of the drug target site and altered drug permeability but there is no cross-resistance with other antibiotics [81].
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in low concentrations. Clinicians should be suspicious of hVISA in
patients with recurrent use of vancomycin, poor clinical response
and a MIC in the intermediately susceptible range [75].
Vancomycin is also ineffective for S. aureus growing in biofilms.
hVISA or any glycopeptides resistance is often associated with
reduced susceptibility or resistance to teicoplanin. The role of
tigecycline, although approved for the treatment of some MRSA
infections, is still unclear in regards to MRSA pneumonia in non-
CF and should be used judiciously [76,77]. In CF tigecycline may
be useful for its concomitant activity against anaerobic bacteria and
atypical mycobacteria [78].
Newermedications forMRSA include quinopristin/dalfopristin
which is not FDA approved for MRSA pneumonia as it was
inferior to other variable treatments. This is similar to daptomycin
which is approved for MRSA therapy for skin infections and
bacteriaemia. It is not recommended for treatment of pneumonia as
it binds to surfactant and eosinophilic pneumonia is one of the side
effects. Fosfomycin is a phosphonic acid derivate with good
activity against gram-negative organisms and available for use in
urinary tract infections. A combination fosfomycin/tobramycin is
being developed as an inhaled antibiotic. In vitro results show good
activity of fosfomycin against MRSA but clinical experience is so
far not available.
7. Conclusion
MSSA and MRSA remain important pathogens both early and
late in the disease course of CF.Although there aremany treatment
options for treating both MSSA and MRSA, many questions
remain regarding the clinical utility and tradeoffs of prophylactic
therapy for MSSA and eradication and treatment for MRSA. To
advance the care ofCF patients, controlled clinical trials are needed
to find the optimal approach to treating and managing CF patients
who are infected with either MSSA or MRSA. Currently no
consensus exists as to how clinicians should manage patients with
CF lung disease who are infected with either MSSA or MRSA.
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